Description
Silvi-ash (Sildenafil + Vardenafil) 100 mg
Silvi-ash is presented as a combination tablet containing sildenafil and vardenafil, both of which are phosphodiesterase type 5 (PDE5) inhibitors used in erectile dysfunction. The trade name itself could not be verified from official regulatory sources, so the description below is based on the verified active ingredients and their established class effects.
Active Ingredient and Medicine Class
Sildenafil and vardenafil belong to the same medicine class: PDE5 inhibitors. These medicines are vasodilators that affect the nitric oxide–cGMP pathway in penile tissue, helping improve erectile function when sexual stimulation is present.
Established Medical Uses
Both sildenafil and vardenafil are established treatments for erectile dysfunction in adult men. Official product information for each ingredient identifies erectile dysfunction as the main approved use for these medicines.
How It Works
PDE5 inhibitors block the enzyme phosphodiesterase type 5, which normally breaks down cyclic guanosine monophosphate (cGMP). By preserving cGMP, these medicines support smooth-muscle relaxation and increased blood flow in the corpus cavernosum, which can help produce and maintain an erection during sexual arousal.
Important Safety Information
These medicines have clinically important safety limits. They must not be used with nitrates or nitric oxide donors because the combination can cause a marked fall in blood pressure. Regulatory information for sildenafil and vardenafil also warns about increased risk with alpha-blockers, some antihypertensives, and strong or moderate CYP3A4 inhibitors such as certain azole antifungals, macrolides, and HIV protease inhibitors. PDE5 inhibitors are also not appropriate for people whose cardiovascular status makes sexual activity inadvisable. Sildenafil and vardenafil have additional precautions in people with low blood pressure and other significant cardiovascular or eye conditions.
This product is a combination of two medicines from the same class, so its safety profile is a concern because class effects may overlap.
Possible Side Effects
Common adverse effects of PDE5 inhibitors include headache, flushing, nasal congestion, dyspepsia, dizziness, and visual disturbances. More serious reactions can include symptomatic hypotension, prolonged erection, sudden hearing changes, and rare serious eye events such as non-arteritic anterior ischemic optic neuropathy.
Scientific Evidence
Peer-reviewed evidence supports both sildenafil and vardenafil as effective PDE5 inhibitors for erectile dysfunction. A systematic review and meta-analysis found sildenafil improved successful intercourse outcomes versus placebo, while a separate meta-analysis found vardenafil significantly improved erectile-function measures compared with placebo. Reviews of head-to-head studies suggest broadly similar efficacy and adverse-event patterns among oral PDE5 inhibitors, though individual response varies.
Medical Information Notice
This educational summary is based on sources available at the time of review and does not replace the official patient leaflet, prescribing information, or assessment by a qualified healthcare professional.
Medical Sources
- DailyMed / FDA: Vardenafil Tablets, Full Prescribing Information. View source
- DailyMed / FDA: Sildenafil Tablets, Full Prescribing Information. View source
- EMA: Viagra EPAR. View source
- Hai Wang et al. “Vardenafil in the Treatment of Male Erectile Dysfunction: A Systematic Review and Meta-Analysis.” Adv Ther. 2021. PubMed
- Howard Fink et al. “Sildenafil for male erectile dysfunction: a systematic review and meta-analysis.” Arch Intern Med. 2002. PubMed
